Lymphocyte-Directed Immunomodulation Remits Thymoma-Associated Autoimmune Pneumonitis

期刊论文
出版模式：

开放获取
发表日期：

2024年7月1日

查看全文

Elise M. N. Ferré,
Diana X. Nichols-Vinueza,
Lindsey B. Rosen,
Peter D. Burbelo,
Kevin P. Fennelly,
Joseph Pechacek,
Daniel M. Goldstein,
Anahita Agharahimi,
Annapurna Saksena,
David E. Kleiner,
Yesim Yilmaz Demirdag,
Arun Rajan,
David S. Schrump,
Steven M. Holland,
Alexandra F. Freeman,
Michail S. Lionakis

摘要

Background

Thymoma presents with several autoimmune manifestations and is associated with secondary autoimmune regulator (AIRE) deficiency. Pneumonitis has recently been described as an autoimmune manifestation associated with thymoma presenting with similar clinical, radiographic, histological, and autoantibody features as seen in patients with inherited AIRE deficiency who suffer from Autoimmune PolyEndocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED) syndrome.

Objectives

To treat two patients with biopsy-proven thymoma-associated pneumonitis with lymphocyte-directed immunomodulation.

Methods

Two patients with thymoma were enrolled on IRB-approved protocols at the NIH Clinical Center. We performed history and physical examination; laboratory, radiographic, histologic and pulmonary function evaluations; and measurement of the lung-directed autoantibodies KCNRG and BPIFB1 prior to and at 1- and 6-months following initiation of lymphocyte-directed immunomodulation with azathioprine with or without rituximab.

Results

Combination T- and B-lymphocyte-directed immunomodulation resulted in improvement of clinical, functional, and radiographic parameters at 6-month follow-up evaluations in both patients with sustained remission up to 12–36 months following treatment initiation.

Conclusion

Lymphocyte-directed immunomodulation remitted autoimmune pneumonitis in two patients with thymoma.